Antibody Information
General Information of This Antibody
| Antibody ID | ANI0OSEHE |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | h1902-11 |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1 |
|||||
| Antigen Name | Claudin-18.2 (CLDN18.2) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
WO2021115426A1 ADC-2 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 84.45% (Day 31) | Moderate CLDN18.2 expression (CLDN18.2 ++) | ||
| Method Description |
Conjugates of the exemplary anti-CLDN18.2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3mpk of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | NUGC4 CDX model | ||||
| In Vitro Model | Gastric signet ring cell adenocarcinoma | NUGC-4 cells | CVCL_3082 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 87.47% (Day 31) | Moderate CLDN18.2 expression (CLDN18.2 ++) | ||
| Method Description |
Conjugates of the exemplary anti-CLDN18.2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10mpk of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | NUGC4 CDX model | ||||
| In Vitro Model | Gastric signet ring cell adenocarcinoma | NUGC-4 cells | CVCL_3082 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.33 nM
|
Positive CLDN18.2 expression (CLDN18.2 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (2-B short reservation).
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.86 nM
|
Positive CLDN18.2 expression (CLDN18.2 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (2-B short reservation).
|
||||
| In Vitro Model | Glioblastoma | U-87MG cells | CVCL_0022 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
2.31 nM
|
Positive CLDN18.2 expression (CLDN18.2 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (2-B long reservation).
|
||||
| In Vitro Model | Glioblastoma | U-87MG cells | CVCL_0022 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
8.11 nM
|
Positive CLDN18.2 expression (CLDN18.2 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (2-B long reservation).
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
WO2021115426A1 ADC-3 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.36 nM
|
Positive CLDN18.2 expression (CLDN18.2 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (short reservation).
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.83 nM
|
Positive CLDN18.2 expression (CLDN18.2 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (short reservation).
|
||||
| In Vitro Model | Glioblastoma | U-87MG cells | CVCL_0022 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
1.67 nM
|
Positive CLDN18.2 expression (CLDN18.2 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (long reservation).
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
2.98 nM
|
Positive CLDN18.2 expression (CLDN18.2 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (long reservation).
|
||||
| In Vitro Model | Glioblastoma | U-87MG cells | CVCL_0022 | ||
WO2021115426A1 ADC-4 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
1.90 nM
|
Positive CLDN18.2 expression (CLDN18.2 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
WO2021115426A1 ADC-5 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
4.81 nM
|
Positive CLDN18.2 expression (CLDN18.2 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
|
||||
| In Vitro Model | Glioblastoma | U-87MG cells | CVCL_0022 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.